Codexis, Inc.
Codexis, Inc. (CDXS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CDXS · as of Jun 8, 2026
Key Statistics
Explore Codexis, Inc. Data
cdxs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 64.3%
The CDXS analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $5.00, representing +92.68% upside from the current price of $2.60.
Competitors & Peers
cdxs competitorsCDXS
ARMP
CCCC
GNFT
IMDX
IPHAStock Performance
Full HistoryAbout Codexis, Inc.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalys…
what is codexis, inc. · cdxs stock overview · codexis, inc. company profile · who is codexis, inc. ceo · cdxs NASDAQ · codexis, inc. headquarters · codexis, inc. business segments
About Stock Overview & Key Data
Codexis, Inc. (CDXS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 22, 2010. As of the latest trading session, CDXS stock price is $2.60, with a market capitalization of $235.9M. The stock has returned +9.03% over the past 12 months and +59.20% year-to-date.
According to 14 Wall Street analysts, the consensus rating for Codexis, Inc. stock is Buy, with an average 12-month price target of $5.00. In fiscal year 2025, Codexis, Inc. reported revenue of $70.4M and net income of -$44.0M. For detailed data — including Codexis, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Codexis, Inc. (CDXS) stock price is $2.60. The stock is traded on NASDAQ under the ticker symbol CDXS. The 52-week range is $0.96 – $3.87.